#COVID-19 vaccine

An extra booster dose raised antibody levels in one third of people with organ transplants, but many remain unprotected.

The protein subunit vaccine provides 100% protection against moderate or severe disease, hospitalization and death.

While the number of breakthrough cases is not trivial, it represents a miniscule proportion of people who are fully vaccinated.

Research suggests how to develop more broadly effective therapies and vaccines.

The same people who have been most vulnerable to COVID-19 are the least likely to be vaccinated.

Pioneering HIV doctor Paul Volberding and veteran activist Gregg Gonsalves reflect on the legacy of AIDS and its implications for COVID-19.

Some unvaccinated Hispanics are worried about missing work or concerned about having to pay for the shots, which are offered at no cost.

Two experimental vaccine approaches, using mRNA protein delivery and germline targeting, are in the early stages of development.

AVAC’s theme for HVAD 2021 is “HIV Vaccine Research: Building on Lessons from COVID.”

The Pfizer-BioNTech vaccine was 100% effective in a study of adolescents; trials for younger children are now underway.

Would-be manufacturers also need technological know-how, trained staff, supplies and raw materials.

The COVID-19 pandemic has profoundly disrupted almost every aspect of the battle against HIV.

Cancer, diabetes and Alzheimer’s would be the initial focus for the proposed agency within the National Institutes of Health.

People with immune deficiency may not respond as well to vaccines but could still gain some protection.

We owe these early fighters a debt of gratitude for transforming our response to public health crises.

An immune balance protocol for pre- and post-vaccination